v3.26.1
Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Deferred tax assets:    
Capitalized research and development costs $ 29,024 $ 38,850
Net operating loss carryforwards 27,713 1,436
Orphan drug credit carryforwards 7,448 2,193
Research and development credit carryforwards 1,326 422
Intangible assets 2,848 2,705
Accrued expenses and other 8,298 6,760
Operating lease liability 1,703 2,287
Gross deferred tax assets 78,360 54,653
Valuation allowance (76,506) (51,753)
Net deferred tax assets 1,854 2,900
Deferred tax liability (1,854) (2,900)
Net deferred tax assets $ 0 $ 0